Here are three notes:
1. Based in Houston, SpinalCyte is a tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts.
2. The article is titled, “Cell Therapy with Human Dermal Fibroblasts Enhances Intervertebral Disc Repair and Decreases Inflammation in the Rabbit Model.”
3. Howard S. An, an orthopedic spine surgeon with Midwest Orthopaedics at Rush in Chicago, led the research team, which also included:
- Ana Chee, PhD
- Peng Shi, PhD
- Thomas D. Cha, MD
- Ting-Hsien Kao, MD, PhD
- Shu-Hua Yang, MD, PhD
- Jun Zhu, MD, PhD
- Ding Chen, MD
- Yeija Zhang, MD, PhD
More articles on devices and implants:
Baird rates Exactech as ‘outperform’: 4 insights
VerteCore finishes 1st week of Lift device crowdfunding: 3 points
Orthofix shares reach new 1-year high: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
